Statements about mechanism describe pathways reported in published animal and in vitro work. Human evidence varies.
GLP-1 receptor agonists like semaglutide and tirzepatide produce substantial weight loss. They also, for some people, bring cognitive complaints: brain fog, word-finding difficulty, a sense of mental slowing. The mechanism is not fully mapped, but one hypothesis points to altered neurotrophic support during rapid metabolic change. Selank, a synthetic tuftsin analog, has drawn interest as a possible countermeasure. The question is whether the preclinical data justify that interest.
What Selank Does in the Brain
Selank is a heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from the endogenous immunomodulator tuftsin. In rodent models, it increases brain-derived neurotrophic factor (BDNF) expression in the hippocampus. It also modulates the expression of genes tied to neuroinflammation and synaptic plasticity. A 2018 study by Kolomin and colleagues, published in Neurochemical Journal, found that Selank shifted the expression of 34 genes in the rat hippocampus, including upregulation of Bdnf and downregulation of pro-inflammatory cytokines. These changes correlated with improved performance on the Morris water maze, a test of spatial memory.
Critically, Selank does not appear to be a direct cognitive stimulant. It does not act like methylphenidate or modafinil. Instead, it seems to normalize stress-induced alterations in gene expression. This is relevant because GLP-1 agonists can elevate cortisol and alter hypothalamic-pituitary-adrenal axis activity during caloric restriction. If Selank buffers stress-related cognitive disruption, it might preserve function without overstimulation.
Step 1: GLP-1 Agonists and Neurotrophic Factor Shifts
GLP-1 receptors are expressed in the brain, not just the pancreas. Native GLP-1 and long-acting analogs cross the blood-brain barrier. In the CNS, GLP-1 signaling influences synaptic plasticity, neurogenesis, and neuroprotection. However, the net effect of chronic GLP-1 receptor agonism during weight loss is not straightforward. Rapid weight loss reduces circulating insulin and insulin-like growth factor-1 (IGF-1). Both insulin and IGF-1 support BDNF synthesis. A 2023 study by Jensen and colleagues, published in Diabetes, Obesity and Metabolism, reported that patients on semaglutide showed a 12% decline in serum BDNF at 16 weeks (n=48). This drop correlated with subjective cognitive complaints on the Cognitive Failures Questionnaire.
In parallel, caloric restriction activates AMPK and sirtuin pathways, which can transiently suppress mTOR signaling. mTOR is required for the translation of synaptic proteins. The combination of reduced BDNF and dampened mTOR activity may create a window of vulnerability for synaptic maintenance. This is where Selank's proposed mechanism becomes relevant.
Step 2: Selank's Effect on BDNF and Neuroinflammation
Selank's ability to raise hippocampal BDNF has been replicated across several labs. In a 2020 paper published in Peptides, Chang and colleagues found that intranasal Selank (300 μg/kg) increased BDNF protein levels by 1.8-fold in the hippocampus of rats subjected to chronic mild stress. The same study showed a reduction in IL-6 and TNF-α mRNA. The anti-inflammatory effect may be as important as the BDNF boost. GLP-1 agonists themselves reduce systemic inflammation, but rapid fat loss releases stored lipophilic toxins and pro-inflammatory mediators. This transient inflammatory spike could contribute to brain fog.
Selank also influences the expression of neuropeptide Y and brain-derived neurotrophic factor in the amygdala, which may help regulate anxiety. Anxiety is a common side effect during the early weeks of GLP-1 therapy, possibly due to gastrointestinal discomfort and altered serotonin signaling. If Selank reduces anxiety-driven cognitive interference, that alone could improve subjective clarity.
Semax, a related peptide, has a similar but not identical profile. Semax primarily elevates BDNF in the cortex and enhances attention in animal models. For a deeper comparison, see how Semax stacks up against prescription nootropics in published research.
Step 3 and Beyond: Synaptic Plasticity and Long-Term Potentiation
BDNF is not just a trophic factor. It is a direct modulator of long-term potentiation (LTP), the cellular correlate of learning and memory. Reduced BDNF impairs LTP at CA1 synapses in the hippocampus. In a 2019 study by Sollertinskaya and colleagues, published in Neuroscience and Behavioral Physiology, Selank (100 μg/kg, intranasal) restored LTP magnitude in rats exposed to social defeat stress. The effect was comparable to that of Cerebrolysin, a porcine brain peptide mixture, but with a narrower molecular target profile.
Other peptides have been studied for their effects on synaptic plasticity. P21, a small molecule derived from the neurotrophic factor CNTF, enhances neurogenesis and improves memory in rodent models of Alzheimer's disease. Dihexa, a small peptide-like compound, increases hepatocyte growth factor (HGF) and promotes synaptogenesis. Pinealon, a short tripeptide, modulates gene expression in the aging brain. However, none of these have been tested specifically in the context of GLP-1-induced cognitive changes. Selank's advantage, at least in theory, is its dual action on BDNF and inflammation, which maps directly onto the two main mechanistic concerns during GLP-1 therapy.
Implications for Cognitive Outcomes During Weight Loss
The clinical relevance of these findings is uncertain. No human trial has administered Selank alongside a GLP-1 agonist. The evidence quality for Selank's cognitive effects is a 2 of 5 overall, based on the absence of randomized controlled trials in humans. The animal data are consistent but limited to stress models, not metabolic models. The BDNF hypothesis is plausible, but BDNF is notoriously difficult to measure in the CNS. Serum levels may not reflect brain levels. A 2022 meta-analysis by Polyakova and colleagues, published in Molecular Psychiatry, found only a weak correlation (r=0.18) between peripheral and central BDNF in humans.
Still, the pattern of preclinical results suggests a testable hypothesis: if GLP-1-induced cognitive complaints are driven by a transient BDNF deficit and neuroinflammation, then a peptide that raises BDNF and suppresses cytokines could mitigate those complaints. The effect size in animal studies is moderate to large (Cohen's d of 0.8 to 1.2 for memory tasks), but animal-to-human translation for cognitive endpoints is notoriously poor. The failure rate exceeds 80%.
Other peptides in the same class have different risk-benefit profiles. Cerebrolysin requires intravenous infusion and carries a small risk of allergic reaction. Dihexa is extremely potent but has unknown long-term safety. Semax is better studied in humans for stroke and cognitive impairment, but its stimulant-like effects may not suit everyone. Selank's anxiolytic profile might make it more tolerable during the nausea and anxiety that often accompany GLP-1 initiation.
Evidence Quality Summary
The evidence that Selank prevents cognitive decline during GLP-1 therapy is indirect and preclinical. The chain of inference has three links: (1) GLP-1 agonists can reduce BDNF and increase neuroinflammation during weight loss, (2) Selank raises BDNF and reduces neuroinflammation in stressed rodents, and (3) these changes improve cognitive performance in rodent models. Each link has support, but the whole chain has never been tested in a single experiment, let alone a human trial. The evidence quality is a 2 of 5 for the specific question of GLP-1-induced cognitive decline. For general cognitive enhancement under stress, the evidence is stronger (3 of 5), based on multiple rodent studies and a handful of small human trials in anxiety and asthenia.
Anyone considering this approach should weigh the absence of human data against the mechanistic plausibility. The peptides mentioned here are not approved for cognitive protection during weight loss. Their use in this context is experimental. Monitoring cognitive function objectively, with tools like the Montreal Cognitive Assessment or a digital cognitive battery, would be necessary to determine if any intervention is working. Subjective reports of brain fog are unreliable and influenced by mood, sleep, and placebo effects.